Efficacy and Safety of HSK21542 in Inducing Postoperative Analgesia in Undergoing Elective Laparoscopic Surgery

NCT ID: NCT04424251

Last Updated: 2024-08-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 124 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-02
• Study Completion Date: 2021-01-05

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled, two-stage phase II clinical study. The main objective is to evaluate the efficacy and safety of HSK21542 injection and explore the recommended dose and administration frequency for subsequent Phase II studies in conjunction with the pharmacodynamic (PD) and pharmacokinetic (PK) characteristics.

Conditions

Analgesia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

stage I：HSK21542 0.4 μg/kg

Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg； intravenous injection

Group Type: EXPERIMENTAL

Experimental: stage I：HSK21542 0.4 μg/kg

Intervention Type: DRUG

Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations

stage I：HSK21542 1 μg/kg

Preoperative:1 μg/kg Postoperative:0.5 μg/kg；intravenous injection

Group Type: EXPERIMENTAL

Experimental: stage I：HSK21542 1 μg/kg

Intervention Type: DRUG

Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations

stage I：HSK21542 0.5μg/kg

Postoperative: 0.5μg/kg；intravenous injection

Group Type: EXPERIMENTAL

Experimental: stage I：HSK21542 0.5μg/kg

Intervention Type: DRUG

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

stage I：HSK21542 1μg/kg

Postoperative: 1μg/kg；intravenous injection

Group Type: EXPERIMENTAL

Experimental: stage I：HSK21542 1μg/kg

Intervention Type: DRUG

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

stage II：HSK21542 0.5μg/kg

Postoperative: 0.5μg/kg；intravenous injection

Group Type: EXPERIMENTAL

Experimental: stage II：HSK21542 0.5μg/kg

Intervention Type: DRUG

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

stage II：HSK21542 1μg/kg

Postoperative: 1μg/kg；intravenous injection

Group Type: EXPERIMENTAL

Experimental: stage II：HSK21542 1μg/kg

Intervention Type: DRUG

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Postoperative: Placebo

Placebo；intravenous injection

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Interventions

Experimental: stage I：HSK21542 0.4 μg/kg

Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations

Intervention Type: DRUG

Experimental: stage I：HSK21542 1 μg/kg

Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations

Intervention Type: DRUG

Experimental: stage I：HSK21542 0.5μg/kg

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Intervention Type: DRUG

Experimental: stage I：HSK21542 1μg/kg

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Intervention Type: DRUG

Experimental: stage II：HSK21542 0.5μg/kg

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Intervention Type: DRUG

Experimental: stage II：HSK21542 1μg/kg

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Intervention Type: DRUG

Placebo

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. 18 ≤ age ≤ 70 years old, with no gender requirement

2. American Society of Anesthesiologists (ASA) Class I-II

3. 18 kg/m^2 ≤ BMI ≤ 40 kg/m^2

4. Subjects undergoing elective laparoscopic surgery under general anesthesia with an expected surgery duration of 1-5 h (inclusive)

5. Agree to participate in this trial and voluntarily sign the informed consent form;

Exclusion Criteria

1. History of allergy to opioids, such as urticaria, or allergic to the intraoperative anesthetics prescribed in the protocol;

2. History or evidence of any one of the following diseases prior to screening:

1. History of cardiovascular diseases: Uncontrolled hypertension (systolic blood pressure [SBP] ≥ 170 mmHg and/or diastolic blood pressure [DBP] ≥ 105 without antihypertensive treatment, or SBP > 160 mmHg and/or DBP > 100 mmHg despite antihypertensive treatment), aneurysm, severe arrhythmia, heart failure, Adams-Stokes syndrome, New York Heart Association (NYHA) Class ≥ III, severe superior vena caval syndrome, pericardial effusion, acute myocardial ischemia, unstable angina, myocardial infarction in the last 6 months before screening, history of tachycardia/bradycardia requiring medication, and II-III degree atrioventricular block (excluding patients with pacemakers);

2. History of respiratory disorder: Severe chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive pulmonary disease, severe bronchostenosis, throat mass, history of (bronchial) tracheoesophageal fistula or airway tear, and severe respiratory tract infection in the last 2 weeks before screening;

3. History of disorders in the nervous and psychiatric system: History of craniocerebral injury, possible convulsions, intracranial hypertension, cerebral aneurysms, and history of cerebrovascular accidents; history of schizophrenia, mania, mental aberration, long-term use of psychotropic drugs, and cognitive disorder; history of depression, anxiety, and epilepsy, etc.;

4. Underwent major surgery within 3 months before screening and was judged by the investigator to have potential effect on the postoperative pain evaluation;

3. Any of the following airway management risks during screening:

1. Acute asthma attacks;

2. Sleep apnea syndrome;

3. History or family history of malignant hyperthermia;

4. History of failed tracheal intubation;

5. Difficult airway (modified Mallampati score ≥ III) as determined by the investigator;

4. In receipt of any of the following drugs or therapies during the screening period:

1. The time between randomization and the last dose of opioid or non-opioid (such as acetaminophen, aspirin [daily dose of > 100 mg], indomethacin, diclofenac, parecoxib sodium and other non-steroidal anti-inflammatory drugs) analgesics is shorter than 5 half-lives of the drug or the duration of drug efficacy (whichever is longer);

2. Continuous use of opioid analgesics for more than 10 days for any reason within 3 months before screening;

3. Use of drugs that affect the analgesic effect within 14 days before randomization, including but not limited to: Sedative hypnotics (benzodiazepines [triazolam, diazepam, midazolam, etc.], non-benzodiazepines [zolpidem, zopiclone, zaleplon, etc.]), sedative anesthetics (sevoflurane, anesthesia ether, nitrous oxide, thiopental, ketamine, etomidate, etc.), glucocorticoids (dexamethasone hydrochloride , methylprednisolone, etc.), anti-epilepsy drugs (carbamazepine, sodium valproate, etc.), anxiolytics (carbamazepine, diazepam, etc.), antidepressants (imipramine, amitriptyline, etc.), and Chinese herbal medicines or Chinese patent medicines with analgesic and sedative effects;

4. Expected to receive anti-tumor drugs and treatments during the period from 14 days before randomization to the end of the follow-up period, including but not limited to chemotherapeutic drugs, targeted drugs, and Chinese herbal medicines.

5. The time between randomization and the last use of diuretics and compound drugs containing diuretic components is shorter than 5 half-lives of the drug or the duration of drug efficacy (whichever is longer);

5. Laboratory test parameters meet one of the following criteria in the screening period and is confirmed by retests:

1. White blood cell count < 3.0 x 10^9/L;

2. Platelet count < 80 x 10^9/L;

3. Hemoglobin <70 g/L;

4. Prothrombin time > 1.5 x ULN;

5. Activated partial thromboplastin time > 1.5 x ULN;

6. Alanine aminotransferase and/or aspartate aminotransferase > 2 x ULN;

7. Total bilirubin > 1.5 x ULN;

8. Blood creatinine > 1.5 x ULN;

9. Fasting blood glucose ≥ 11.1 mmol/L;

6. Without oxygen supplement during the screening period, the pulse oxygen saturation is < 92%;

7. During the screening period, the virological examination for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), treponema pallidum antibody, or human immunodeficiency virus (HIV) antibody is positive;

8. History of drug abuse, narcotics use and/or alcohol abuse within 3 months before screening. Alcohol abuse is defined as > 2 units of alcohol consumption per day (1 unit = 360 mL of beer containing 5% alcohol, 45 mL of liquor containing 40% alcohol, or 150 mL of wine);

9. Donated or lost ≥ 400 mL of blood within 3 months before screening;

10. Participated in any drug clinical trials within 3 months before screening (defined as the administration of the investigational product or placebo);

11. Women who are pregnant or breastfeeding; fertile women or men who are unwilling to use contraception during the trial; subjects who are planning pregnancy within 3 month after the completion of the trial (including male subjects);

12. Subjects determined by the investigator to be unsuitable for participating in this clinical study for any other reason.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, , China

Countries

China

References

Zhong Y, Wang H, Yan M, Yang M, Zhang J, Nan L, Wang Z, Yang J, Wu J, Guo Q, Hu X, Xu H, Xu Q, Wang D. Efficacy and safety of peripherally-restricted kappa-opioid receptor agonist-HSK21542 for postoperative analgesia in patients undergoing laparoscopic abdominal surgery: a randomized, placebo-controlled phase 2 trial. Front Med (Lausanne). 2025 Jul 24;12:1604790. doi: 10.3389/fmed.2025.1604790. eCollection 2025.

Reference Type: DERIVED

PMID: 40776930 (View on PubMed)

Other Identifiers

HSK21542-201

Identifier Type: -

Identifier Source: org_study_id